Clinical development of atypical antipsychotics: research design and evaluation. Collaborative Working Group on Clinical Trial Evaluations.
Clinical trials support the efficacy and safety of new drugs on the market. They provide the United States Food and Drug Administration with the information needed to approve an Investigational New Drug application and are the basis for package inserts provided by the manufacturers that guide clinicians in the use of a new drug. Because clinical trials are vital to the effective and safe use of new drugs, it is important to understand who participates in them, what questions are answered by clinical trials, and what questions are raised. The reader who asks the proper questions about issues such as methodology, affiliations of the investigators, statistical analyses performed, location of study centers, and study populations will derive the most information from the report of a clinical trial.
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods* / Q000592:standards* / Q000706:statistics & numerical data; D003431:Cross-Cultural Comparison; D004334:Drug Administration Schedule; D017277:Drug Approval / Q000331:legislation & jurisprudence; D015507:Drugs, Investigational / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D005060:Europe; D005260:Female; D006801:Humans; D008297:Male; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012107:Research Design / Q000592:standards / Q000706:statistics & numerical data; D012559:Schizophrenia / Q000188:drug therapy; D014481:United States; D014486:United States Food and Drug Administration
D014150:Antipsychotic Agents; D015507:Drugs, Investigational; D010919:Placebos